All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 15,482 as of Monday, July 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,893 issues advancing vs. 1,042 declining with 108 unchanged. The Health Services industry currently sits up 0.7% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include MiMedx Group ( MDXG), down 8.1%, and Fresenius Medical Care AG & Co. KGaA ( FMS), down 0.7%. Top gainers within the industry include WellCare Health Plans ( WCG), up 3.3%, Centene Corporation ( CNC), up 1.6%, Cooper Companies ( COO), up 1.4%, CareFusion ( CFN), up 1.1% and Laboratory Corporation of America Holdings ( LH), up 0.8%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Mindray Medical International ( MR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mindray Medical International is down $1.02 (-2.7%) to $36.85 on heavy volume. Thus far, 637,607 shares of Mindray Medical International exchanged hands as compared to its average daily volume of 721,600 shares. The stock has ranged in price between $36.13-$37.29 after having opened the day at $36.40 as compared to the previous trading day's close of $37.87. Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $4.5 billion and is part of the health care sector. Shares are up 17.2% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Mindray Medical International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Mindray Medical International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.